1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2022, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (= 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 3, 3 and 1 respectively.
Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypereosinophilic Syndrome - Overview
- Hypereosinophilic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypereosinophilic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
- Hypereosinophilic Syndrome - Drug Profiles
- Hypereosinophilic Syndrome - Dormant Projects
- Hypereosinophilic Syndrome - Product Development Milestones
- Featured News & Press Releases
- Nov 17, 2021: European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases
- Sep 17, 2021: GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases
- Sep 15, 2021: NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
- Jan 15, 2021: Knopp Biosciences reports positive trial results of oral asthma drug
- Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
- Sep 28, 2020: GSK’s Nucala receives FDA approval to treat HES
- Sep 16, 2020: Knopp Biosciences completes enrollment in phase 2 trial of oral dexpramipexole in eosinophilic asthma
- May 27, 2020: FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
- Dec 03, 2019: Knopp to start trial enrollment of oral dexpramipexole in H1 2020
- Nov 14, 2019: GSK reports positive data for Nucala in late-stage HES trial
- Aug 19, 2019: Knopp begins study of dexpramipexole in eosinophilic asthma patients
- Jul 09, 2019: Knopp Biosciences to present clinical data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
- Apr 24, 2019: Knopp Biosciences receives FDA Orphan Drug Designation for Dexpramipexole for treatment of Hypereosinophilic Syndrome
- Apr 05, 2019: Study finds AstraZeneca’s asthma drug could treat immune disorder
- Apr 03, 2019: FDA-approved drug effectively treats rare chronic immune disorder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hypereosinophilic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
- Hypereosinophilic Syndrome - Pipeline by Areteia Therapeutics Inc, 2022
- Hypereosinophilic Syndrome - Pipeline by GSK plc, 2022
- Hypereosinophilic Syndrome - Pipeline by Incyte Corp, 2022
- Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, 2022
- Hypereosinophilic Syndrome - Pipeline by Nexeos Bio, 2022
- Hypereosinophilic Syndrome - Dormant Projects, 2022
- Number of Products under Development for Hypereosinophilic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Areteia Therapeutics Inc
- GSK plc
- Incyte Corp
- Kyowa Kirin Co Ltd
- Nexeos Bio
